Fistula Healing in Pivotal Studies of Ustekinumab in Crohn's Disease

Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Jean‐Frédéric Colombel(Mount Sinai Hospital), Christopher Gasink(Janssen (United States)), Long-Long Gao(Janssen (United States)), Willem J. de Villiers(Western University), Jewel Johanns(Johnson & Johnson (United States))
Gastroenterology
April 1, 2017
10.1016/s0016-5085(17)30930-7
Cited by 82

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k